A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)

Date Added
August 8th, 2022
PRO Number
Pro00121904
Researcher
Marc-Andre Cornier

List of Studies

Keywords
Cholesterol, Drug Studies, Heart
Summary

If you are an adult over 40 years of age with atherosclerosis cardiovascular disease (heart attack or ischemic stroke or narrowing of arteries in legs due to plaque) and a LDL cholesterol greater than 70 mg/dL, you may be eligible to take part in a clinical research study. The purpose of this study is to evaluate the benefit of inclisiran on major cardiovascular events while taking either atorvastatin or rosuvastatin cholesterol lowering medications. Study participants will be randomly assigned to take either inclisiran or placebo (inactive medication). Study visits during the treatment period will occur every three months twice and then every six months for up to six years. If eligible, study medication and study visits will be provided free of charge. Compensation is available.

Institution
MUSC
Recruitment Contact
Lori Spillers
843-876-0977
spillerl@musc.edu



-- OR --